Cargando…
MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy
Numerous clinical trials of mesenchymal stromal/stem cells (MSCs) as a new treatment for coronavirus-induced disease (COVID-19) have been registered recently, most of them based on intravenous (IV) infusion. There is no approved effective therapy for COVID-19, but MSC therapies have shown first prom...
Autores principales: | Moll, Guido, Drzeniek, Norman, Kamhieh-Milz, Julian, Geissler, Sven, Volk, Hans-Dieter, Reinke, Petra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249852/ https://www.ncbi.nlm.nih.gov/pubmed/32574263 http://dx.doi.org/10.3389/fimmu.2020.01091 |
Ejemplares similares
-
Bio-instructive hydrogel expands the paracrine potency of mesenchymal stem cells
por: Drzeniek, Norman M, et al.
Publicado: (2021) -
Preclinical Toxicity Evaluation of Clinical Grade Placenta-Derived Decidua Stromal Cells
por: Sadeghi, Behnam, et al.
Publicado: (2019) -
Oxidative Stress Is Predominant in Female but Not in Male Patients with Autoimmune Thrombocytopenia
por: Kamhieh-Milz, Julian, et al.
Publicado: (2014) -
Thromboprophylaxis for Coagulopathy Related to COVID-19 in Pediatrics: A Narrative Review
por: Sahrai, Hadi, et al.
Publicado: (2023) -
Multi-Parameter Analysis of Biobanked Human Bone Marrow Stromal Cells Shows Little Influence for Donor Age and Mild Comorbidities on Phenotypic and Functional Properties
por: Andrzejewska, Anastazja, et al.
Publicado: (2019)